Your browser is old and is not supported. Upgrade for better security.

Invest in Squid Healthcare

The only FDA seeking product to address periocular post-procedure care

Highlights

1
πŸ“ˆ Huge market opportunity >$1B annually for an unmet medical & aesthetic need, growing at 15% CAGR
2
πŸš€ FDA 510(k) authorization (Rx & OTC) submitted after successfully completing testing requirements
3
πŸ† Patent issued on utility, composition, design, and formulation(s)
4
πŸ‘¨πŸΎβ€πŸ”¬πŸ‘¨πŸΌβ€βš•οΈ Co-founders are scientist with 15 yrs industry experience and oculoplastic surgeon
5
πŸ›  Exclusive manufacturing agreement and production line with an international manufacturer
6
πŸ’° Founders-funded and seeking a SAFE round for team build-up, Series A, & 2022 commercialization

Our Team

There is a clear consumer and patient need for periocular post-procedure management and we are excited to provide an effective solution that will be the only FDA authorized product on the market and that will positively impact the lives of our consumers and patients.

Pitch

Overview